Artimplant: Artelon(R) STT Spacer Receives Regulatory Clearance for Marketing in the USA.VASTRA FROLUNDA, Sweden -- The biomaterials company Artimplant (STO:ARTIB) receives regulatory clearance for marketing Artelon[R] STT STT State Street Corporation (stock symbol) STT Suomen Tietotoimisto (Finnish National News Agency) STT Secure Transaction Technology STT Surface Tension Transfer (welding) Spacer in the USA. The product is indicated for osteoarthritis in the STT joint. Small Bone Innovations, the licensee of Artimplant, now gets the opportunity to market the product at its domestic market USA. Patients in the USA with osteoarthritis in both the CMC (Common Messaging Calls) A programming interface specified by the XAPIA as the standard messaging API for X.400 and other messaging systems. CMC is intended to provide a common API for applications that want to become mail enabled. 1. and STT joints that previously could not be treated for thumb base osteoarthritis with only Artelon[R] CMC Spacer will as of now have the possibility to benefit from Artimplant's Artelon[R] Spacers in both joints. President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Hans Rosen says; "Artelon[R] STT Spacer is an important complement to our currently best selling product Artelon[R] CMC Spacer. In addition each new Artelon[R] product that receives regulatory clearance increases market awareness of the unique capacity of Artelon[R] in various medical applications." About Artimplant Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production, and marketing of degradable de·grad·a·ble adj. That can be chemically degraded: degradable plastic wastes. de·grad implants that regenerate body functions and improve quality of life. Our products, made from Artelon[R], meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications. Artimplant is a public company listed on the OMX OMX Office Max (stock symbol) Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector. Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence ob·so·les·cent adj. 1. Being in the process of passing out of use or usefulness; becoming obsolete. 2. Biology Gradually disappearing; imperfectly or only slightly developed. ; general economic conditions; and other risks detailed from time to time in the Company's filings. This information was brought to you by Cision http://newsroom.cision.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion